Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia
Sponsor: Gilead Sciences
A PHASE1 clinical study on Chronic Lymphocytic Leukemia and Follicular Lymphoma, this trial is completed. The trial is conducted by Gilead Sciences and has accumulated 10 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE1
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .